Regeneron drug 100% reduces symptomatic infection, say makers

Regeneron drug 100% reduces symptomatic infection, say makers

On January 21, Eli Lilly reported similar results in its own COVID-19 antibody, bamlanivimab, which was tested in nursing home facilities. Complete trial data from the study is expected early in the second quarter, the company said.

The company on Tuesday also presented early data from a late-stage trial showing that its combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in COVID-19 patients by 70%.

A two-drug antibody cocktail from Regeneron Pharmaceuticals called REGEN-COV prevents COVID-19 in people exposed to an infected household member, preliminary data suggest.

The new antibody targeting the South Africa variant is swiftly moving toward human testing, according to a company executive.

"The initial supply was purchased by the federal government which allocates it to the states/territories, who then allocate it to hospitals or infusion centers in their region".

Explained: Why health experts in the U.S. are now recommending ‘double masking’
The CDC has not recommended the public use N95 respirators as N95s should be reserved for health care workers. Marr said while N95s are the gold standard, they are not the only acceptable face mask.

A passive vaccine works by giving patients the antibodies directly, while regular vaccines work by injecting a weakened version of the virus, allowing the body's immune system to develop antibodies naturally to fight off the virus. And tests of blood from people who got either of the COVID-19 vaccines from Pfizer Inc or Moderna Inc showed antibodies generated by the shots were less effective against the South Africa variant, although Moderna has said it still believes its vaccine will provide protection. In the cocktail group, infections lasted no more than one week, while about 40% in the placebo cohort lasted three to four weeks.

While the FDA would still need to approve the drug for this passive vaccine use, Regeneron's President and Chief Scientific Officer, Dr. George Yancopoulos, said it could help to slow the transmission of the virus.

The company said the treatment reduced viral levels and improved symptoms in the patients, many of whom were at risk of worsening to severe disease because they were at least 65 years old, obese or had another health condition.

The Regeneron study also found that adverse events occurred more frequently in the placebo group, 18% placebo compared to 12% on REGEN-COV.

Related Articles